APDN:NSD-Applied DNA Sciences Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 1.34

Change

+0.09 (+7.20)%

Market Cap

USD 0.02B

Volume

0.34M

Avg Analyst Target

USD 6.00 (+347.76%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


APDN Stock Forecast & Price:
Based on the Applied DNA Sciences Inc stock forecasts from 1 analysts, the average analyst target price for Applied DNA Sciences Inc is USD 6.00 over the next 12 months. Applied DNA Sciences Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Applied DNA Sciences Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Applied DNA Sciences Inc’s stock price was USD 1.34. Applied DNA Sciences Inc’s stock price has changed by -26.37% over the past week, -57.73% over the past month and -76.28% over the last year.

About Applied DNA Sciences Inc (APDN:NSD)

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina Inc

+2.72 (+1.48%)

USD28.96B 41.47 80.65
IDXX IDEXX Laboratories Inc

-1.49 (-0.45%)

USD27.82B 42.20 30.36
ICLR ICON PLC

-0.48 (-0.26%)

USD15.56B 107.82 20.64
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
EXAS EXACT Sciences Corporation

-0.37 (-1.14%)

USD5.72B N/A -14.05
GH Guardant Health Inc

+1.54 (+3.20%)

USD5.00B N/A -11.02
SYNH INC Research Holdings Inc

-1.12 (-2.35%)

USD4.89B 18.25 11.58
MEDP Medpace Holdings Inc

+0.82 (+0.56%)

USD4.51B 27.02 18.89
NTRA Natera Inc

+0.57 (+1.34%)

USD4.20B N/A -7.22
NEOG Neogen Corporation

-0.30 (-2.06%)

USD3.20B 33.61 34.20

ETFs Containing APDN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -66.67% 39% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.67% 39% F 20% F
Trailing 12 Months  
Capital Gain -75.23% 36% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.23% 36% F 20% F
Trailing 5 Years  
Capital Gain -49.05% 52% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.05% 52% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain 353.02% 98% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 353.02% 98% A+ 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 867.00% 4% F 2% F
Risk Adjusted Return 40.72% 72% C- 75% C
Market Capitalization 0.02B 13% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.56 39% F 30% F
Price / Cash Flow Ratio -1.29 44% F 50% F
EV/EBITDA -1.18 62% D- 61% D-
Management Effectiveness  
Return on Equity -108.26% 20% F 15% F
Return on Invested Capital -136.76% 10% F 12% F
Return on Assets -56.24% 5% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.05 100% A+ 96% A
Short Percent 7.35% 20% F 21% F
Beta 0.07 91% A- 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector